# The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment

Study · id `cardio:ct-nct02575092` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02575092](<https://clinicaltrials.gov/study/NCT02575092>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02575092

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4000 participants.

## Technical summary

Registry record NCT02575092. Randomized; double masking; primary purpose treatment. Start 2015-11-01 (actual); primary completion 2019-02-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 4000 participants (enrolled count; ClinicalTrials.gov record NCT02575092, source copy `cardio:ctgov-nct02575092-2019-08-06`, retrieved 2026-10-26)
- Started: 2015-11-01 (actual) (ClinicalTrials.gov record NCT02575092, source copy `cardio:ctgov-nct02575092-2019-08-06`, retrieved 2026-10-26)
- Primary completion: 2019-02-10 (actual) (ClinicalTrials.gov record NCT02575092, source copy `cardio:ctgov-nct02575092-2019-08-06`, retrieved 2026-10-26)
- Completion: 2019-07-31 (actual) (ClinicalTrials.gov record NCT02575092, source copy `cardio:ctgov-nct02575092-2019-08-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02575092, source copy `cardio:ctgov-nct02575092-2019-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02575092-2019-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment
- Acronym: CONTRAST-CADT
- Condition: Homocysteine
- Condition: Coronary Disease
- Condition: Angioplasty,Balloon,Coronary
- Condition: Contrast Media
- Condition: Nephropathy
- Condition: Hypertension
- Intervention (Drug): Enalapril Maleate Tablets(as the program-based antihypertension)
- Intervention (Drug): Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)
- Intervention (Drug): Placebo
- Lead sponsor: Fuling Central Hospital of Chongqing City
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: b27eef4b6a7f608590c3b6d12441480deecfd2191c7aa7a2407245556cc1f0d5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
